Gavrilov I, Nacheva M, Tzingilev D
Department of Thoracic Surgery, National Oncological Centre, Sofia, Bulgaria.
J BUON. 2002 Jan-Mar;7(1):61-5.
To identify differences in clinical characteristics, histological features, hormone receptor status, and tumor marker expression between patients with sporadic and familial breast cancer.
As in the previous Part I of this study, two groups of women with breast cancer were compared. The first group (group I) included 504 patients with a family history of breast cancer. The second (control) group (group II) consisted of 300 patients not reporting such a history in their relatives. The examined parameters in this report were stage and axillary lymph node involvement at the time of the initial diagnosis, treatment methods, hormone receptor status, and serum levels of the tumor markers CEA and CA 15.3. The data were processed and analysed using the SPSS statistical package. The statistical significance of differences between groups and subgroups was evaluated by x(2) Pearson's test and Student's paired t-test.
Compared to sporadic cases, patients with familial breast cancer were more often diagnosed at an advanced III or IV stage; metastatic involvement of the regional lymph nodes was more frequent in group I patients. In the same group more radical surgical procedures combined with chemotherapy and local irradiation were performed. In group I the percentage of negative hormone receptors was higher (35.3% versus 22.6%; p <0.0001) for estrogen receptors (ER), and 47.6% versus 32.6% (p <0.0001) for progesterone receptors (PR). Also, in group I raised serum levels of CA 15.3 were significantly more frequent compared with group II (48% versus 35.5%, p <0.0789), and this applied also for CEA values above 50 ng/ml (10.6% versus 1.5%, p <0.0002).
Familial breast cancer displays particular clinical characteristics, distinguishing it from the sporadic type of the disease. Patients with familial breast cancer are usually diagnosed at an advanced stage. Commonly, the hormone receptors are negative and the serum concentrations of tumor markers elevated. The steroid receptor status represents the most reliable predictor of response to hormonotherapy and an important prognostic factor of the patient's outcome. As a result of their particular characteristics, these patients require more radical surgical techniques combined with pre- or postoperative local radiotherapy and systemic chemotherapy.
鉴别散发性乳腺癌和家族性乳腺癌患者在临床特征、组织学特征、激素受体状态及肿瘤标志物表达方面的差异。
如本研究之前的第一部分,对两组乳腺癌女性患者进行比较。第一组(I组)包括504例有乳腺癌家族史的患者。第二组(对照组,II组)由300例亲属中无此类病史报告的患者组成。本报告中所检测的参数包括初次诊断时的分期和腋窝淋巴结受累情况、治疗方法、激素受体状态以及肿瘤标志物癌胚抗原(CEA)和糖类抗原15.3(CA 15.3)的血清水平。使用SPSS统计软件包对数据进行处理和分析。通过Pearson卡方检验和学生配对t检验评估组间及亚组间差异的统计学意义。
与散发性病例相比,家族性乳腺癌患者更常被诊断为III期或IV期晚期;I组患者区域淋巴结转移受累更为常见。在同一组中,更多地采用了根治性手术联合化疗及局部放疗。在I组中,雌激素受体(ER)阴性的比例更高(35.3% 对22.6%;p <0.0001),孕激素受体(PR)阴性的比例为47.6% 对32.6%(p <0.0001)。此外,与II组相比,I组中CA 15.3血清水平升高的情况明显更为常见(48% 对35.5%,p <0.0789),CEA值高于50 ng/ml的情况也是如此(10.6% 对1.5%,p <0.0002)。
家族性乳腺癌表现出特定的临床特征,使其有别于散发性乳腺癌。家族性乳腺癌患者通常在晚期被诊断出来。通常,激素受体为阴性,肿瘤标志物的血清浓度升高。类固醇受体状态是激素治疗反应最可靠的预测指标,也是患者预后的重要因素。由于其特殊的特征,这些患者需要更激进的手术技术联合术前或术后局部放疗及全身化疗。